Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry

Autor: Zhang, Junfen, Boesjes, Celeste M., Loman, Laura, Kamphuis, Esmé, Romeijn, Margreet L.E., Spekhorst, Lotte S., Haeck, Inge, van der Gang, Lian F., Dekkers, Coco C., van der Rijst, Lisa P., Oosting, Albert J., van Lumig, Paula, van Lynden-van Nes, Anneke M.T., Tupker, Ron A., Nijssen, Annieke, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R.H., Christoffers, Wianda A., Stewart, Shiarra M., Kamsteeg, Marijke, de Graaf, Marlies, de Bruin-Weller, Marjolein S., Schuttelaar, Marie-Louise A.
Zdroj: In Journal of the American Academy of Dermatology August 2024 91(2):300-311
Databáze: ScienceDirect
Externí odkaz: